Aptus pharma limited IPO Overview
Aptus pharma limited IPO is a SME public issue offered through a Book Building issue with a total issue size of ₹13.02 Cr. The IPO price band is set at ₹65 to ₹70 per share, and retail investors can apply with a minimum investment of ₹2.80 L as per IPO guidelines.
The Aptus pharma limited IPO opens on 23 Sept 2025 and closes on 25 Sept 2025. The IPO allotment is expected to be finalized on 26 Sept 2025, and the equity shares are proposed to be listed on BSE on 30 Sept 2025.
Investors can refer to the Aptus pharma limited IPO RHP-DRHP for detailed information. The issue is managed by Interactive Financial Services Ltd. as the book running lead manager, while Bigshare Services Pvt Ltd is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About aptus pharma limited
The company manufactures and distributors of a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more.
Products:
Aptus Pharma: Focuses on acute therapies i.e, anti-infectives, pain management, etc.
Aptus CD care: Focused on chronic therapies
Aptus Wellcare: Offers wellness and nutraceutical products
Aptus Global: Export in overseas market
As of March 31, 2025, the company has 194 pharmaceutical formulations in more than eleven therapeutic segments.
Its warehouse is located over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model includes 125 direct and sub distributors and a sales team of 54 field personnel.
As of March 31, 2025, the company had 70 employees.
Competitive Strengths
Diversified product portfolio
Robust distribution network
Strategic manufacturing alliances across Gujarat, Uttarakhand and Himachal Pradesh
Competitive and cost-effective pricing
Experienced management team
Investment Objective
Working Capital
General corporate purposes